Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
DERRICK SCOTT ROBERTSON, MD Curriculum Vitae October 2016 Mailing Address: University of South Florida Morsani College of Medicine Department of Neurology 12901 Bruce B. Downs Blvd. MDC 55 Tampa, Florida 33612 Practice Address: Carol and Frank Morsani Center for Advanced Healthcare University of South Florida 13330 USF Laurel Drive Tampa, Florida 33612 Contact Information: [email protected] Telephone: 813 974-3541 Fax Number: 813 905-9838 Education: University of South Florida, B.S. Interdisciplinary Natural Sciences (Cum Laude) Tampa, Florida 1999 – 2003 University of South Florida, College of Medicine Doctor of Medicine Tampa, Florida 2004 – 2008 Medicine Internship University of South Florida, College of Medicine Tampa, Florida 2008 – 2009 Neurology Residency Chief Resident University of South Florida, College of Medicine Tampa, Florida 2009 – 2012 2011 – 2012 Multiple Sclerosis Fellowship University of South Florida, College of Medicine Tampa, Florida 2012 Professional Experience Assistant Professor, Department of Neurology University of South Florida, College of Medicine 2012-Present Director, Multiple Sclerosis Division Department of Neurology University of South Florida, College of Medicine 2012-Present Program Director, Multiple Sclerosis Fellowship Department of Neurology University of South Florida, College of Medicine 2012-Present Associate Program Director, Neurology Residency Department of Neurology University of South Florida, College of Medicine 2012-Present Licensures State of Florida, Medical #ME113374 Certifications Board Certified in Neurology, American Board of Psychiatry and Neurology 2012-Present Leadership Positions: Elected Director, Board of Directors University of South Florida Physicians Group University of South Florida, College of Medicine Tampa, Florida 2015 – Present Executive Management Committee on Research University of South Florida, College of Medicine Tampa, Florida 2015 – Present Program Evaluation Committee 2014 – Present Neurology Residency Program, Department of Neurology University of South Florida, College of Medicine Tampa, Florida Resident Clinical Competency Committee 2014 – Present Neurology Residency Program, Department of Neurology University of South Florida, College of Medicine Tampa, Florida Vice-Chief Tampa General Hospital, Department of Neurology Tampa, Florida 2014 –2016 Continuing Professional Development Committee University of South Florida, College of Medicine Tampa, Florida 2013 – Present Clinical Advisory Committee National Multiple Sclerosis Society Mid-Florida Chapter 2013 – Present MS Step-Up Leadership Steering Committee National Multiple Sclerosis Society Mid-Florida Chapter 2013 – Present Graduate Medical Education Committee, University of South Florida, Tampa, Florida 2011 – Present Chief Resident, Neurology Residency, University of South Florida, Tampa, Florida 2011 – 2012 Awards Resident of the Year, University of South Florida Tampa, Florida 2012 Resident Scholarship, Foundation of the Consortium of Multiple Sclerosis Centers Annual Meeting, San Diego, CA 2012 Resident Scholarship, American Academy of Neurology Annual Meeting, New Orleans, LA 2012 Resident Scholarship, Fundamentals of Pain Management: 2011 A Primer for Residents and Fellows Course, Annual American Pain Society Scientific Meeting, Austin, Texas Resident Travel Award, Florida Society of Neurology Annual Meeting, Orlando, Florida 2010 – 2011 Teaching courses: MDT 8800 Neuroimmunology Component in Neurological Diseases MEL 8677 Outpatient Neurology MEL 8690 Research in Neurology GMS 6708 Neuroimmunology PHA 6783 Pharmacotherapeutics II Professional Society Memberships: American Neurological Association American Academy of Neurology Florida Society of Neurology American Pain Society Florida Medical Association 2013 – Present 2009 – Present 2009 – Present 2011 – 2012 2004 – 2013 Publications, Peer-reviewed Gangadhara S, Gangadhara S, Gandhy C, Robertson D. Rhabdomyolysis and autoimmune variant Stiff-Person syndrome. Clin Pract. October 2016. Submitted. Miller W, Konstas D, Gandhy C, Robertson D. Diagnosis of an acute, late-onset parenchymal Neuro-Behcet’s disease without systemic manifestations. Case Rep Neurol Med 2016;2016:5720319. Robertson D, Moreo N. Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations. Fed Pract 2016 June;33(06):28-33. Heekin R, Gandhy C, Robertson D. Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination. Case Rep Neurol 2015;7:78-83. Benbadis S, Sanchez-Ramos, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Zesiewicz T. Medical Marijuana in Neurology. Expert Rev Neurother. 2014 Dec;14(12):1453-65. Selected Abstract Presentations: Moreo N, Deng D, Lyman M, Soares R, Gandhy C, Robertson D. Assessing the Incidence of Lymphopenia with the Use of Dimethyl Fumarate in Multiple Sclerosis. Poster presentation at the Consortium of Multiple Sclerosis Centers Annual Meeting, National Harbor, MD, 2016. Moreo N, Deng D, Lyman M, Soares R, Gandhy C, Robertson D. Assessing the Incidence of Elevation in Eosinophils with the Use of Dimethyl Fumarate in Multiple Sclerosis. Poster presentation at the Consortium of Multiple Sclerosis Centers Annual Meeting, National Harbor, MD, 2016. Tillman E, Luther J, Casady L, Robertson D, Stephenson J. Free from Falls Program at the University of South Florida. Poster presentation at the Consortium of Multiple Sclerosis Centers Annual Meeting, National Harbor, MD, 2016. Dixon C, Aungst A, Calma A, Gandhy C, Robertson D. Rapid Elimination Procedure of Teriflunomide with Colestipol Hydrochloride. Poster presentation at the American Neurological Association Annual Meeting, Indianapolis, IN, 2015. Patel, P, Ganghadhara, S, Robertson D. Paroxsymal Nonkinesiogenic Dyskinesia as a Presenting Symptom of Multiple Sclerosis: Case Report. Poster presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, 2014 Sista, R, Stephens, H, Robertson D. Refractory Simple Partial Seizures in a Patient with Relapsing-remitting Multiple Sclerosis: Case Report. Poster presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, 2014 Sista, R, Stephens, H, Robertson D. Copper Deficiency Myeloneuropathy Misdiagnosed as Vitamin B12 Deficiency: Case Report. Poster presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, 2014 Lwin W, Robertson D, Standley K. Isolated Cognitive Disturbance as an Indicator of Acute Relapse in Multiple Sclerosis. Poster presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, 2013 Masi S, Robertson D, Butler M, Casady L, Seevers A. The effect of natalizumab on Sexual Dysfunction in Multiple Sclerosis. Poster presentation as works-in-progress at The 23rd Annual USF Health Research Day, Tampa, Florida, 2013 Robertson D, Casady L, Aungst A. Measuring Adherence to Tecfidera in Multiple Sclerosis Patients. Poster presentation as works-in-progress at The Consortium of Multiple Sclerosis Centers, Orlando, Florida, 2013 Robertson D, Muntean E. Balό’s Concentric Sclerosis Presenting as a Ring-enhancing Lesion in a HIV-infected Patient. Case Report. Poster Presentation at the American Society of Neuroimaging Annual Meeting, Miami, Florida, 2012 Robertson D, Bozorg A. Can multiple drug allergies predict the final diagnosis in patients undergoing video-EEG monitoring? Poster Presentation at the American Epilepsy Society Annual Meeting, San Antonio, Texas, 2010 Robertson D, Muntean E, Tsakadze N. Isolated Sphenoid Sinus Aspergillosis Presenting as Cavernous Sinus Syndrome. Case Report. Poster Presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, 2009 Presentations/Invited Lectures: Differential Diagnosis of Multiple Sclerosis and Diagnostic Challenges. Grand Rounds, University of South Florida, Department of Neurology. Role: Invited Lecturer. October 2016. 5th Annual Khan GME Today Advanced Practice Seminar in Multiple Sclerosis. CME Program, PRIME Education, Inc. Role: Faculty. Tampa, Florida. October 2016. 9th Annual Chair Summit. CME Program, CME Outfitters, LLC. Role: Lecturer. Miami, Florida. September 2016. Differential Diagnosis of Multiple Sclerosis and Diagnostic Challenges. Grand Rounds, University of South Alabama, Department of Neurology. Role: Invited Lecturer. Mobile, Alabama. September 2016. 3D MS THRIVE Initiative: Clinical Management and Patient Outcomes in Multiple Sclerosis. CME Program, Med Learning Group. Role: Lecturer. Melbourne, Florida. August 2016. Novel Insights on the Interplay of B cells and T cells in Therapeutic Management of Multiple Sclerosis. CME Program, PRIME Education, Inc. Role: Lecturer. Tampa, Florida. June 2016. Year in Review: Advances in the Treatment of Multiple Sclerosis. CME Program, PRIME Education, Inc. Role: Lecturer. Tampa, Florida. February 2016. Cognitive Errors in Medical Decision Making. Grand Rounds, University of South Florida, Department of Neurology. Role: Invited Lecturer. December 2015. Year in Review: Advances in the Treatment of Multiple Sclerosis. CME Program, PRIME Education, Inc. Role: Lecturer. Tampa, Florida. November 2015. 6th Annual Updates from ECTRIMS: Highlights in Research and Treatment of Multiple Sclerosis. CME Program, PRIME Education, Inc. Role: Lecturer. Tampa, Florida. October 2014. MacIver S, Robertson D. “Chronic Relapsing Inflammatory Optic Neuropathy (CRION): Case Report and Current Treatments”. Platform Presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, September 2014 5th Annual Updates from ECTRIMS: Highlights in Research and Treatment of Multiple Sclerosis. CME Program, PRIME Education, Inc. Role: Lecturer. Tampa, Florida. October 2013. Multiple Sclerosis Expert Panel: National Multiple Sclerosis Society Mid-Florida Chapter 14th Annual Day of Discovery. Orlando, Florida. December 2012. New and Emerging Therapies in MS. Keynote Speaker: National Multiple Sclerosis Society Mid-Florida Chapter Annual Meeting and Research Symposium. Tampa, Florida. October, 2012. Robertson D, Bozorg A. “Periodic Regional Epileptiform Discharges (PREDs): A Proposal for a New Electroencephalographic Definition”. Platform Presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, September 2011. Robertson D, Bozorg A. “Can multiple drug allergies predict the final diagnosis in patients undergoing video-EEG monitoring?” Platform Presentation at the Florida Society of Neurology Annual Meeting, Orlando, Florida, September 2010. Research: Multi-center, randomized, double-blinded assessment of Tecfidera® in extending the time to a first attack in radiologically isolated syndrome February 2016 Principal Investigator Biogen Status: Enrolling An Open-label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who have had Suboptimal Response to an Adequate Course of Disease-Modifying Treatment January 2016 Principal Investigator Genentech Status: Enrolling An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects with Relapsing-Remitting Multiple Sclerosis January 2016 Principal Investigator Biogen Status: Enrolling A Phase 3b multicenter, randomized, parallel-group, open-label study to evaluate the effects of ocrelizumab on immune responses in patients with relapsing forms of multiple sclerosis November 2015 Principal Investigator Genentech Status: Enrolling A Phase 2a/2b double-blind, randomized, placebo-controlled study assessing efficacy, safety, and dose-response of vatelizumab in patients with relapsing-remitting multiple sclerosis (RRMS) April 2015 Principal Investigator Genzyme Status: Closed A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis April 2015 Principal Investigator Biogen Status: Closed OPTIMUM: Oral Ponesimod versus Teriflunomide In relapsing MUltiple sclerosis Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis April 2015 Principal Investigator Actelion Status: Enrolling A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE) November 2014 Principal Investigator Biogen Idec, Inc. Status: Closed Rapid Elimination Procedure of Teriflunomide with Colestipol Hydrochloride (Investigator Initiated Trial) October 2014 Principal Investigator Status: Enrolling Grant Funding provided by Genzyme A multicenter, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from Tysabri®(natalizumab) to Tecfidera® (dimethyl fumarate) September 201 Principal Investigator Biogen Status: Closed A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) April 2014 Principal Investigator Biogen Status: Enrolling A single-center prospective measurement of adherence to treatment with Tecfidera™ in multiple sclerosis patients (Investigator Initiated Trial) March 2014 Principal Investigator Status: Active Grant Funding provided by Biogen A Placebo-controlled Randomized withdrawal evaluation of the efficacy and safety of Baclofen ER capsules (GRS) in subjects with spasticity due to Multiple Sclerosis August 2013 Principal Investigator Sun Pharma Status: Enrolling A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate October 2013 Principal Investigator Biogen Status: Closed A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis May 2013 Principal Investigator Novartis Status: Active A Phase I, Multi-center, Open-Label Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Intravenous MEDI-551 in subjects with Multiple Sclerosis (MS)# CD-IA-MEDI-551-1102 May 2013 Principal Investigator MedImmune Status: Active A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients with Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (dimethyl fumarate) delayed-release capsules April 2013 Principal Investigator Biogen Status: Closed A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ Administration of Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis January 2012 Sub-Investigator Glaxo Smith Kline Status: Closed A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis who are Treated with Interferon-beta #EFC6058 November 2011 Sub-Investigator Genzyme Status: Closed A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis November 2011 Sub-Investigator Avanir Pharmaceuticals Status: Closed A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients with Relapsing Multiple Sclerosis September 2011 Principal Investigator F. Hoffman-La Roche Ltd/Genentech Status: Active A Multicenter, Randomized, Double-blinded, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis September 2011 Principal Investigator Biogen Status: Active A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients September 2011 Principal Investigator Biogen Status: Closed The Effect of Natalizumab on Sexual Dysfunction in Multiple Sclerosis (Investigator Initiated Trial) September 2010 Sub-Investigator Status: Closed Grant Funding provided by Biogen A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis. #109MS303 May 2010 Principal Investigator Biogen Status: Active An Extension Protocol For Multiple Sclerosis Patients Who Participated in GenzymeSponsored Studies of Alemtuzumab April 2009 Principal Investigator Genzyme Status: Active